News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TG Therapeutics, Inc. (MHA) Announces Presentation of Pre-Clinical Data on the Combination of TG-1101 and TGR-1202 at the International Conference on Malignant Lymphoma, Lugano, Switzerland


6/19/2013 9:33:14 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NEW YORK, June 19, 2013 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs, today announced pre-clinical data on the combination of TG-1101 plus TGR-1202 was presented in the Novel Monoclonal Antibodies Oral Session during the 12th International Conference on Malignant Lymphoma which was held in Lugano, Switzerland.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   
Lymphoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES